Evidence map›Paper›PMID 27183642›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2016

Immunodominant West Nile Virus T Cell Epitopes Are Fewer in Number and Fashionably Late.

Saghar Kaabinejadian, Curtis P McMurtrey, Sojung Kim, Rinki Jain, Wilfried Bardet, Fredda B Schafer, Jason L Davenport, Aaron D Martin, Michael S Diamond, Jon A Weidanz and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Saghar KaabinejadianDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104;
Curtis P McMurtreyDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104;
Sojung KimDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110;
Rinki JainCenter for Immunotherapeutic Research, Texas Tech University Health Sciences Center School of Pharmacy, Abilene, TX 79601; Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center School of Pharmacy, Abilene, TX 79601; Receptor Logic, Inc., Abilene, TX 79601;
Wilfried BardetDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104;
Fredda B SchaferDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104;
Jason L DavenportSensiQ Technologies, Inc., Oklahoma City, OK 73104;
Aaron D MartinSensiQ Technologies, Inc., Oklahoma City, OK 73104;ORCID 0000-0001-6213-7430
Michael S DiamondDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110; Department of Medicine, Washington University School of Medicine, St Louis, MO 63110; and Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO 63110.
Jon A WeidanzCenter for Immunotherapeutic Research, Texas Tech University Health Sciences Center School of Pharmacy, Abilene, TX 79601; Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center School of Pharmacy, Abilene, TX 79601; Receptor Logic, Inc., Abilene, TX 79601;
Ted H HansenDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110;
William H HildebrandDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104; William-Hildebrand@ouhsc.edu.
University of Oklahoma Health Sciences Center · USWashington University in St. Louis · USTexas Tech University · US

Funding

Discovery and Targeting of West Nile Virus EpitopesU01AI082057 · NIAID · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HILDEBRAND, WILLIAM · 2009 to 2013
$5.3M
NIAID NIH HHS HHSN266200400027CNIAID NIH HHS U01 AI082057
6 · The paper itself

Abstract

Class I HLA molecules mark infected cells for immune targeting by presenting pathogen-encoded peptides on the cell surface. Characterization of viral peptides unique to infected cells is important for understanding CD8(+) T cell responses and for the development of T cell-based immunotherapies. Having previously reported a series of West Nile virus (WNV) epitopes that are naturally presented by HLA-A*02:01, in this study we generated TCR mimic (TCRm) mAbs to three of these peptide/HLA complexes-the immunodominant SVG9 (E protein), the subdominant SLF9 (NS4B protein), and the immunorecessive YTM9 (NS3 protein)-and used these TCRm mAbs to stain WNV-infected cell lines and primary APCs. TCRm staining of WNV-infected cells demonstrated that the immunorecessive YTM9 appeared several hours earlier and at 5- to 10-fold greater density than the more immunogenic SLF9 and SVG9 ligands, respectively. Moreover, staining following inhibition of the TAP demonstrated that all three viral ligands were presented in a TAP-dependent manner despite originating from different cellular compartments. To our knowledge, this study represents the first use of TCRm mAbs to define the kinetics and magnitude of HLA presentation for a series of epitopes encoded by one virus, and the results depict a pattern whereby individual epitopes differ considerably in abundance and availability. The observations that immunodominant ligands can be found at lower levels and at later time points after infection suggest that a reevaluation of the factors that combine to shape T cell reactivity may be warranted.

Indexed as

Antigen PresentationAnimalsAntibodies, MonoclonalAntibody SpecificityCD8-Positive T-LymphocytesCell Line, TumorDendritic CellsEpitopes, T-LymphocyteFemaleHLA-A AntigensHumansImmunodominant EpitopesMiceMice, Inbred BALB CReceptors, Antigen, T-CellWest Nile virusAntibodies, MonoclonalEpitopes, T-LymphocyteHLA-A AntigensImmunodominant EpitopesReceptors, Antigen, T-Cell

Identifiers

PMID27183642
PMCPMC4874531
OpenAlexW2338353336

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.